Subsequently, the TPO protein expression was evaluated in samples from all fifty-six breast cancer patients by immunohistochemistry using a broad panel of TPO-specific monoclonal antibodies that recognize linear (mAb 47, mAb A4, and ab76935) or conformational (mAb 18 and mAb 64) epitopes of the TPO immunodominant region. Here, TPO is linked to breast cancer.